*BIONEXUS GENE LAB CORP. COMPLETES STRATEGIC INVESTMENT IN FIDELION DIAGNOSTICS; SECURES 15% EQUITY STAKE IN GLOBAL AI-ONCOLOGY PLATFORM AND EXCLUSIVE SOUTHEAST ASIAN RIGHTS FOR VITAGUARD™
*BIONEXUS GENE LAB CORP - BUYS 15% EQUITY STAKE IN FIDELION DIAGNOSTICS
((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))
Source Date/Time = 03-DEC-202513:45:00.16 GMT